

# ASX Announcement

Medibio Limited – 24 October 2019



## Medibio Signs Agreement with PwC Australia for ilumen™

**Melbourne, Australia and Minneapolis, MN – 24 October 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF)**, a health technology company is pleased to announce today that it has signed an agreement to provide access to ilumen™ to PwC Australia.

ilumen™ will be made available to all PwC Australia personnel, commencing in October 2019 for a term of 12 months. This agreement follows a successful program that Medibio conducted for PwC Australia in 2018.

“We are pleased to be able to work with PwC Australia to offer their workforce a better understanding of their mental wellbeing,” said Jennifer Solitario, Senior Vice President of Corporate Health. “PwC are leading the way in implementing programs that assure, as much as possible, the wellbeing of their workforce. To that end, ilumen™ will provide PwC Australia management with de-identified aggregate data to better support and manage the mental wellbeing of their workforce.

ilumen™ will also offer participants with early screening for symptoms of depression, anxiety, and stress. The ilumen™ biometric data and subjective assessments provide users with a ‘wellbeing snapshot’ that they use to monitor and make improvements over time; whilst also providing management with de-identified aggregate data to better support and manage the mental wellbeing of their workforce.

According to PwC Chief People Officer Dorothy Hisgrove, “Our people value the opportunity to know where they’re at with their mental health. Initiatives such as this program are helping us to ‘dial up’ the dialogue around mental wellbeing across the firm, and increase our people’s awareness of the support that’s available to them at PwC.”

David B. Kaysen, Chairman, Managing Director and CEO said, “This agreement further demonstrates the interest and the need that we are seeing from the market in a variety of geographies for this technology. We are focused on developing additional long-term agreements after other clients complete various pilot trials.”

– ENDS –

# ASX Announcement

Medibio Limited – 24 October 2019



## About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental wellbeing solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).

<b>Further Information:</b>	Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a>
<b>Medibio Media Enquiries:</b> Kristi Hamilton Director, Strategic Communications Medibio Limited <a href="mailto:kristi.hamilton@medibio.com.au">kristi.hamilton@medibio.com.au</a> T: +1 952 232 0934	<b>Australian Investor Enquiries:</b> Peter Taylor NWR Communications <a href="mailto:peter@nwrcommunications.com.au">peter@nwrcommunications.com.au</a> T: +61 (0) 412 036 231